Dr. Fisher on Bortezomib/R-CHOP Combo for Mantle Cell Lymphoma

Richard Fisher
Published: Wednesday, Jan 07, 2015



Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.

A phase 2 study of this combination showed promising results. While the level of toxicities were minimal during the trial, there were some cases of neurotoxicity.
Fisher says that the results of the trial show the potential of bortezomib as a treatment option for patients with mantle cell lymphoma.


Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.

A phase 2 study of this combination showed promising results. While the level of toxicities were minimal during the trial, there were some cases of neurotoxicity.
Fisher says that the results of the trial show the potential of bortezomib as a treatment option for patients with mantle cell lymphoma.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x